ACLX
Arcellx, Inc.
$71.28
-0.49
(-0.68%)
| Exchange: | NASDAQ |
| Market Cap: | 3.953B |
| Shares Outstanding: | 165581 |
About The Company
| Sector: | Healthcare | |||||
| Industry: | Biotechnology | |||||
| CEO: | Rami Elghandour | |||||
| Full Time Employees: | 163 | |||||
| Address: |
|
|||||
| Website: | https://arcellx.com |
Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company’s lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It is also developing ACLX-001, an immunotherapeutic combination composed of ARC-T cells and bi-valent SparX proteins targeting BCMA to treat r/r MM; ACLX-002 and ACLX-003 for treating r/r acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS); and other AML/MDS product candidates, as well as solid tumor programs. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Gaithersburg, Maryland.
Click to read more…
Revenue Segmentation
🔒 You are currently logged out
Income Statement
(* All numbers are in thousands)
🔒 You are currently logged out
Balance Sheet
(* All numbers are in thousands)
🔒 You are currently logged out
Cash Flow Statement
(* All numbers are in thousands)
🔒 You are currently logged out
Analyst Estimates
(* All numbers are in thousands)
🔒 You are currently logged out
Current Key Metrics
🔒 You are currently logged out
Forward P/E Ratios
🔒 You are currently logged out
SWOT Analysis
🔒 You are currently logged out
At what price to buy it? –
Intrinsic Value Calculator
🔒 Premium Feature
Log in to access the ACLX Intrinsic Value Calculator
Get comprehensive stock analysis with premium features
🔒 You are currently logged out
MS_Stock_Embed class not found. Please check plugin configuration.